Friday, November 20, 2026

News

Demis Hassabis's Isomorphic Labs Raises $5 Billion Series C, Still Without a Clinical Candidate

BusinessPatryk Raba
Demis Hassabis's Isomorphic Labs Raises $5 Billion Series C, Still Without a Clinical Candidate
Fot. Duncan.Hull, Wikimedia Commons (CC BY-SA 4.0)

London-based Isomorphic Labs, spun out of the Alphabet orbit, announced a $5 billion Series C led by Greenoaks and Sequoia. The company did not disclose a valuation or any drug candidate in the clinic.

Contents
  1. Who is in the round
  2. What the money is for
  3. No candidate in the clinic
  4. Hassabis and pharma partners

Isomorphic Labs, the AI drug-design company founded by Demis Hassabis, announced a $5 billion Series C round on November 17, 2026. According to BioSpace, it is the largest single venture round in biotech history. The company still has not disclosed a single molecule or clinical program.

Who is in the round

Greenoaks and Sequoia Capital co-lead the round. Andreessen Horowitz joins as a new investor, and Alphabet continues to back the company. All existing investors took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund, the company said.

Isomorphic did not give a post-round valuation. TechCrunch notes that Bloomberg reported earlier in November that the company was seeking funding at a $50 billion valuation; the company has not disclosed a new valuation.

What the money is for

According to the company's announcement, the funds are meant to speed up scientific progress and the development of its own AI models. The company is scaling its drug design engine and its pipeline of AI-designed therapeutic candidates. BioSpace, citing the company, describes the engine as a suite of foundational simulation AI models that work across multiple therapeutic areas and drug modalities.

Hassabis said the round will let the company accelerate work on its first therapeutic programs heading toward clinical trials. BioSpace adds that, according to the company, Isomorphic is also building an ecosystem of partners and the global infrastructure needed to power AI-led bioengineering.

Our drug design engine is generating molecules with unprecedented precision and speed - Demis Hassabis, founder and CEO of Isomorphic Labs (quoted by BioSpace)

No candidate in the clinic

BioSpace points out that the company has not yet reached the clinic and has not publicly disclosed any assets. The company reports positive preclinical results in internal programs in oncology and immunology, as TechCrunch and BioSpace both note.

The combination is unusual: according to BioSpace, investors have recently preferred more mature, lower-risk assets. The preclinical results described are the company's own claims, with no independent verification in the sources we used.

Hassabis and pharma partners

CNBC notes the round came about three and a half months after Hassabis stepped back as CEO of DeepMind. According to TechCrunch, the move was made to focus on drug discovery, and Hassabis took a chairman role at DeepMind; this is Isomorphic's first fundraise since that change. The company has deals with pharmaceutical firms including Eli Lilly, Novartis and Johnson & Johnson.

For Polish readers, this is above all a signal of the scale of capital flowing into AI in biotechnology, and of investors paying for the promise of a platform before any clinical data exists. Whether Isomorphic's engine translates into medicines will be decided only by the first human trials, for which the company has not yet given a timeline.

Share: